Dr. Massimo CristofanilliAdmissions Committee
Massimo Cristofanilli, MD, FACP
Professor of Medicine
Robert Lurie Cancer Center, Northwestern University
Dr. Cristofanilli reciveived his medical degree in 1986 from the University “La Sapienza” Medical School in Rome (Italy) where he subsequently completed a Fellowship in Medical Oncology in November 1990. In July 1996, he started a Medical Oncology Fellowship at the University of Texas M. D. Anderson Cancer Center.
Dr Christian RolfoEducational Committee
Prof. Dr. Christian Rolfo, MD, PhD, MBA
He was born in Córdoba, Argentina in 1972; studied at the National University of Córdoba, graduating from the medical school in 1996. In 1998 he began his studies at the University of Milan, Italy.
Prof. Dr. María José SerranoCentro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica | GENYO · ONCOLOGICAL RESEARCH. CTC GROUP
Dr. Juan José Díaz MochónTREASURER ISLB
Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica | GENYO · NanochemBio
Dr. Luis Paz-AresHospital Universitario 12 de Octubre, Madrid, Spain
Media Relations Committee
Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate
Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology
Research Center), all in Madrid, Spain.
Dr. José Luis CostaClinical Implementation Committee
He is the Scientific Coordinator of the Genomics Core Facility and Principal Investigator at the newly established i3S - Instituto de Investigação e Inovação em Saúde. His career has focused on understanding the crucial genetic events that are the basis for the development and progression of cancer. To develop his work, he uses diverse genomic techniques, ranging from basic molecular biology tools to high-throughput technologies.
Prof. Joaquin DopazoComputational Committee
Director of the Bioinformatics Area, Fundacion Progreso y Salud, Sevilla, Spain
Clinical Bioinformatics Area, Fundacion Progreso y Salud,
CDCA, Hospital Virgen del Rocío, C/Manuel Siurot s/n.
Prof. Jesus Garcia-Foncillas MD PhDAudit Committee
University Cancer Institute “OncoHealth”
University Hospital “Fundacion Jimenez Diaz”
Autonomous University of Madrid, Spain
Dr. Ignacio Gil-BazoLiquid Biopsy Samples Repository Committee
Chairman of Oncology Department
Codirector of the Lung Cancer Program
Associate Professor of Oncology (School of Medicine, University of Navarra)
Principal investigator at the Center for Applied Medical Research (CIMA)
Dr. Ignacio DuranPublications Committee
Ignacio Durán, MD, PhD
Hospital Universitario ‘Virgen del Rocio’
Dr Durán is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Spanish Society of Medical Oncology. His major research interests include genitourinary tumours and anticancer clinical drug development. He has authored numerous publications covering diverse areas of medical oncology in peer-reviewed scientific journals.
Dr. Eduardo Díaz-RubioGrants And Prizes Committee
Catedrático y Jefe Servicio Oncología Médica
Académico de Número de la Real Academia Nacional de Medicina
Hospital Universitario Clínico San Carlos
Facultad de Medicina, Universidad Complutense, Madrid.
Dr. Umberto MalapelleChair of Young Investigators
Assistant Professor in Anatomic Pathology in School of Medicine.
Department of Public Health, University Federico II of Naples
Dr Evi LianidouProfessor of Analytical Chemistry – Clinical Chemistry
Dr. Evi Lianidou is Professor of Analytical Chemistry and Clinical Chemistry at the Department of Chemistry, University of Athens, Greece. Dr Lianidou has established a Molecular Diagnostics Laboratory focused on Liquid Biopsy at the Department of Chemistry since 1998
Dr Raghu KalluriProfessor and Chairman, Department of Cancer Biology
University of Texas MD Anderson Cancer Center. USA
Dr David GandaraUniversity of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
David R. Gandara, MD is a Professor of Medicine at the University of California at Davis (UCD) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center (UCDCCC). He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology.
Dr Bernardino Alcázar NavarreteLicenciado en Medicina y Cirugía. Universidad de Granada y Especialista en Neumología (Hospital Universitario Virgen de las Nieves de Granada). Actualmente es Facultativo Especialista de Neumología en el Hospital de Alta Resolución de Loja (Granada).
Su investigación clínica se centra en EPOC y asma bronquial, en la identificación de biomarcadores de respuesta al tratamiento inhalado en la EPOC, así como patrones de aparición de exacerbaciones frecuentes y consumo de recursos sanitarios.
Dr Leticia De Mattos ArrudaDr Leticia De Mattos-Arruda, MD, PhD is a physician scientist medical oncologist at the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. She worked at the VHIO conducting clinical trials and translational research projects from 2009 to 2014. In 2010, she was a recipient of the European Society for Medical Oncology (ESMO) Translational Research Fellowship and attended the 12o ECCO - AACR - EORTC - ESMO Workshop on Methods in Clinical Cancer Research.
Dr Filip JankuDepartment of Investigational Cancer Therapeutics, Division of Cancer Medicine
Dr Raghu KalluriMD Anderson
Professor and Chairman, Department of Cancer Biology
University of Texas MD Anderson Cancer Center
*Adjunct Professor of Molecular and Cellular Biology
Baylor College of Medicine
*Adjunct Professor of Bioengineering
Dr. Manish KohliHuntsman Cancer Institute- University of Utah, USA.
The research of Manish Kohli, M.D., is focused on identifying biomarkers with predictive and prognostic impact in patients with advanced prostate cancer, advanced kidney cancer, advanced bladder cancer and all stages of testicular cancer.
In the Division of Medical Oncology at Mayo Clinic, Dr. Kohli also conducts and oversees phase I, II and III clinical trials in the advanced stages of these malignancies.
Dr Valerie FraserCancer Research, Education and Public Policy Advocate
Director of Research and Advocacy
Inflammatory Breast Cancer International Consortium (ibcic.org)
Valerie serves as Officer and Director of Research and Advocacy for the Inflammatory
Breast Cancer International Consortium (ibcic.org). As a cancer research advocate she
has served on clinical trial working groups, scientific review panels, agent selection
committees, steering committees and advisory groups and as an advocate consultant
Dr. Todd E. DruleyTodd E. Druley, MD, PhD is the Chief Medical Officer for ArcherDX, Inc. He is also an Associate Professor of Pediatrics, Genetics and Developmental Biology at Washington University School of Medicine in St. Louis. His work focuses on improved molecular diagnostics for precision cancer therapy as well as pediatric cancer predisposition.
Dr. Jose Luis García GiménezEl Dr. García Giménez se licenció en Ciencias Químicas en 2002 y dos años después obtuvo su licenciatura en Bioquímica por la Universitat de València. En el año 2007 finalizó su tesis doctoral en el Departamento de Química Inorgánica de la Facultat de Farmacia obteniendo el grado de doctor con sobresaliente “cum laude”.
es investigador post-doctoral del Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) e Investigador del Instituto de Investigación Sanitaria INCLIVA
Dr. Matteo AllegrettiOncogenomic and Epigenetic Unit
Department of Research, Advanced diagnostics and Technological innovation
IRCSS Regina Elena National Cancer Institute
Via E. Chianesi 53, 00144, Rome
Dr Manu CarolloOxford Brookes University
graduated in 2015 with a 1st Class Honours with Distinction BSc/MSc in Chemistry and Pharmaceutical Technology at the University of Naples Federico II. I then undertook lab placements at Swansea, Newcastle and Cambridge Universities where I specialized in cancer biology and metastasis research. I then started to work in the Carter lab in 2017.
Dr Tim ForshewTim is both Head of Science and Innovation and co-founder of Inivata. He is also an honorary lecturer at UCL. Prior to Inivata, during his time at Cambridge University and Cancer Research UK, Tim was part of the team that first published detecting solid tumour mutations through next generation sequencing of cell free DNA. As a postdoctoral Researcher he won the 2009 Jeremy Jass Prize for his role in identifying fusion genes in Pilocytic Astrocytoma.